Figure 3.

Montelukast and carfilzomib inhibited MM cell growth in vivo. BALB/c nu/nu mice bearing MM.1S tumors were treated with montelukast (15mg/kg; intraperitoneally) daily in the presence and/or absence of carfilzomib (2 mg/kg; intraperitoneally) for 21 days. Tumor volumes (a) and the weight of mice (b) were measured every 3 days. NOD/SCID mice bearing RPMI 8226 tumors were treated with montelukast (15 mg/kg; intraperitoneally) daily in the presence and/or absence of carfilzomib (2 mg/kg; intraperitoneally) for 14 days. Tumor volumes (d) and the weight of mice (e) were measured every 2 days. The tumor volumes were calculated using the following formula: V = (length × width²)/2. (c and f) Tumor sections from 4 groups were subjected to immunostaining using TUNEL and anti-Ki67/c-Myc Abs and demonstrated tumor cell apoptosis and proliferation. *P ≤ 0.05 compared with other groups. **P ≤ 0.001compared with other groups. MNK: montelukast. CFZ: carfilzomib. CTL: control.